General：Sunitinib, also known as malate sunitinib or sortan, is a multi-target tyrosine kinase inhibitor that can inhibit multiple receptor tyrosine kinases (RTKs). Some receptor tyrosine kinases are involved in tumor growth, pathological angiogenesis, and tumor metastasis. Therefore, sunitinib has multiple effects on inhibiting tumor angiogenesis and anti-tumor cell production and metastasis.

Product introduce：The primary development goal of sunitinib is to treat gastrointestinal stromal tumors and metastatic renal cell carcinoma that are unresponsive or intolerant to standard therapies. Sunitinib can selectively target receptors of certain proteins, which are believed to play a molecular switch like role in tumor growth. The above indications for sunitinib have been granted "fast track" approval status by the FDA in the United States.